| Literature DB >> 35745165 |
Monika Grabia1, Renata Markiewicz-Żukowska1, Katarzyna Socha1, Agnieszka Polkowska2, Aneta Zasim2, Karolina Boruch3, Artur Bossowski2.
Abstract
The occurrence of metabolic syndrome (MetS) significantly affects the course of diabetes mellitus (DM), resulting in deterioration of insulin sensitivity and metabolic control, as well as many cardiometabolic complications. The aim of the study was to investigate the relationships between cardiovascular biomarkers, nutritional status, dietary factors and the occurrence of MetS among 120 participants from northeast Poland (adolescents with type 1 DM and healthy peers). MetS was assessed using several criteria: nutritional status by anthropometric measurements, body composition analysis by bioelectrical impedance, and diet using a food diary and questionnaire. MetS was diagnosed in every third diabetic. Compared to healthy peers, MetS patients had higher total body fat (26% vs. 14%, p < 0.001) and visceral fat (77 cm2 vs. 35 cm2, p < 0.001), and lower total antioxidant status (1.249 mmol/L vs. 1.579 mmol/L, p < 0.001). Additionally, their diet was rich in saturated fatty acids, but low in dietary fiber as well as mono- and polyunsaturated fatty acids. The group of diabetics reported many inappropriate eating behaviors. The combination of those with the presence of an excessive content of visceral fat tissue and abnormal values of MetS components may negatively affect metabolic control, thus accelerating the development of cardiometabolic complications.Entities:
Keywords: adolescents; antioxidant status; body composition; continuous glucose monitoring; diabetes type 1; insulin therapy; metabolic syndrome; nutrients intake; nutritional status; obesity
Mesh:
Substances:
Year: 2022 PMID: 35745165 PMCID: PMC9228781 DOI: 10.3390/nu14122435
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Flowchart of the inclusion process in the study.
Nutritional standards for children and adolescents.
| Nutrients | Polish Standards for Healthy Children [ | Diabetes Poland Standards [ | ISPAD Standards [ |
|---|---|---|---|
| Protein | 10–20% | 15–20% | 15–20% |
| Carbohydrates | 45–65% | 45% (up to 60% | 45–50% |
| Fat | 20–35% | 25–40% | up to 30–35% |
| SFA | as low as possible | <10% | <10% |
| MUFA | - | <20% | - |
| PUFA | - | 6–10% | - |
| EPA + DHA | 250 mg | - | - |
| ALA | 0.5% | - | - |
| LA | 4% | - | - |
| Dietary fiber | 19 g (10–15 y), | >25 g or 15 g/1000 kcal | Age (y) + 5 g |
Percentage values are expressed as total daily energy intake. Abbreviations: alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), glycemic index (GI), International Society for Pediatric and Adolescent Diabetes (ISPAD), linoleic acid (LA), monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA), saturated fatty acids (SFA), years (y).
Figure 2Criteria of metabolic syndrome (MetS) diagnosis in children and adolescents [7,8,9,14].
Characteristics of the study cohort.
| Parameter | Participants | |
|---|---|---|
| with T1DM ( | without T1DM ( | |
| Me ± IQR | ||
| Age (years) | 14 (12–16) | 15 (13–16) |
| Body height (cm) | 166 (156–173) | 168 (162–176) |
| Body weight (kg) | 54 (45–66) | 58 (47–69) |
| Age of diagnosis (years) | 9 (7–11) | |
| Diabetes duration (years) | 5 (2–7) | |
| HbA1c (%) | 7.6 (6.6–10.2) | |
| Gender (girls/boys) | 27 (45%)/33 (55%) | 16 (27%)/44 (73%) |
| Type of insulin therapy (MDI/CSII) | 23 (38%)/37 (52%) | |
| Type of glucose-monitoring system (FGM/CGM) | 18 (70%)/8 (30%) | |
Values are expressed as median and interquartile range (Me (Q1–Q3) or number and percentage of respondents (n (%)). Abbreviations: continuous glucose monitoring (CGM), continuous subcutaneous insulin infusion (CSII), flash glucose monitoring (FGM), multiple daily injections (MDI), type 1 diabetes mellitus (T1DM).
Prevalence of metabolic syndrome, based on various criteria.
| Criteria | T1DM Group ( | Patients without T1DM ( | ||
|---|---|---|---|---|
| Total | Girls/Boys | Total | Girls/Boys | |
| ATP | 15 (25%) | 11 (41%)/4 (12%) | 3 (5%) | 1 (6%)/2 (5%) |
| IDF | 5 (8%) | 3 (11%)/2 (6%) | 3 (5%) | 0/3 (7%) |
| WHO | 8 (13%) | 4 (15%)/4 (12%) | 1 (2%) | 0/1 (2%) |
| Grabia et al. | 11 (18%) | 9 (33%)/2 (6%) | 1 (2%) | 0/1 (2%) |
Values are expressed as a number and percentage of respondents (n (%)). Abbreviations: National Cholesterol Education Program Adult Treatment Panel III (ATP), International Diabetes Federation (IDF), type 1 diabetes mellitus (T1DM), World Health Organization (WHO).
Comparison of cardiovascular biomarkers.
| Parameter | MetS+ ( | MetS− ( | Control Group ( | ||
|---|---|---|---|---|---|
| Me ± IQR | MetS+ vs. MetS− | MetS+ vs. Control | |||
| WC (cm) | 73 (69–78) | 66 (62–70) | 70 (67–74) | <0.001 | N/S |
| WHR | 0.87 (0.84–0.9) | 0.87 (0.81–0.91) | 0.88 (0.85–0.92) | N/S | N/S |
| WHtR | 0.40 (0.39–0.42) | 0.40 (0.38–0.42) | 0.44 (0.42–0.48) | <0.001 | <0.001 |
| BMI (kg/m2) | 22.6 (19.9–24.5) | 19.8 (17.9–21.2) | 20.3 (18.6–22.0) | <0.01 | <0.5 |
| FGL (mg/dL) | - | - | 98 (93–103) | - | - |
| HbA1c (%) | 8.9 (7.4–11.4) | 6.9 (6.4–9.2) | - | <0.001 | - |
| eGDR (mg/kg/min) | 8.0 (6.3–10.0) | 10.8 (8.8–11.6) | - | <0.001 | - |
| TC (mg/dL) | 157 (124–187) | 148 (123–170) | 143 (131–187) | N/S | N/S |
| LDL-ch (mg/dL) | 102 (74–111) | 80 (66–101) | 86 (76–110) | <0.5 | N/S |
| HDL-ch (mg/dL) | 44.5 (34.5–57.5) | 59 (48–71) | 57 (52–64) | <0.001 | <0.001 |
| TG (mg/dL) | 101 (67–143) | 60 (47–91) | 59 (45–76) | <0.001 | <0.001 |
| SBP (mmHg) | 120 (110–128) | 114 (109–118) | 118 (110–125) | <0.5 | N/S |
| DBP (mmHg) | 74 (70–80) | 70 (66–73) | 70 (65–74) | <0.01 | <0.5 |
Values are expressed as median and interquartile range (Me (Q1–Q3). Statistically significant differences between the medians were detected by the Mann–Whitney U test. Abbreviations: National Cholesterol Education Program Adult Treatment Panel III (ATP), body mass index (BMI), diastolic blood pressure (DBP), estimated glucose disposal resistance (eGDR), fasting glucose level (FGL), high-density lipoprotein cholesterol (HDL-ch), glycated hemoglobin (HbA1c), International Diabetes Federation (IDF), low-density lipoprotein cholesterol (LDL-ch), metabolic syndrome (MetS), systolic blood pressure (SBP), total cholesterol (TC), triglycerides (TG), waist circumference (WC), waist–hip ratio (WHR), waist-to-height ratio (WHtR), World Health Organization (WHO).
Figure 3Percentage of participants meeting the metabolic syndrome components. Values are expressed as percentage of respondents (%). WHR (acc.BMI) includes the percentage of persons who are overweight or obese and, additionally, have a WHR above normal. BMI classifications for underweight, overweight, and obesity in the pediatric population correspond to the 10th, 85th, and 97th percentiles, respectively. Abbreviations: National Cholesterol Education Program Adult Treatment Panel III (ATP), body mass index (BMI), diastolic blood pressure (DBP), high-density lipoprotein cholesterol (HDL-ch), International Diabetes Federation (IDF), metabolic syndrome (MetS), systolic blood pressure (SBP), type 1 diabetes mellitus (T1DM), triglycerides (TG), waist circumference (WC), World Health Organization (WHO), waist–hip ratio (WHR), waist-to-height ratio (WHtR).
HbA1c and TAS values, depending on metabolic control.
| Study Group | HbA1c (%) | TAS (mmol/L) | HbA1c Group | HbA1c | HbA1c (%) | TAS (mmol/L) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Me ± IQR | Me ± IQR | Me ± IQR | ||||||||
| MetS+ | 8.9 | 1.249 | MetS+ vs. MetS− |
| 3 (12%) | <0.01 | 6.7 | <0.001 | 1.230 | MetS+HbA1c>7% |
|
| 17 (49%) | 9.9 | 1.243 | |||||||
| MetS− | 6.9 | 1.394 | MetS+ vs. Control |
| 22 (88%) | 6.4 | <0.001 | 1.403 | ||
|
| 18 (51%) | 9.7 | 1.370 | |||||||
| Control group | - | 1.579 | - | |||||||
Values are expressed as median and interquartile range (Me (Q1–Q3) or number and percentage of respondents (n (%)). Statistically significant differences between the medians or percentages were detected by the Mann–Whitney U or the chi-squared test, respectively. Abbreviations: glycated hemoglobin (HbA1c), metabolic syndrome (MetS), total antioxidant status (TAS).
Comparison of body-composition analysis parameters.
| Parameter | MetS+ ( | MetS− ( | Control Group ( | ||
|---|---|---|---|---|---|
| Me ± IQR | MetS+ vs. MetS− | MetS+ vs. Control | |||
| Body weight (kg) | 64 (52–73) | 52 (43–59) | 58 (48–68) | <0.5 | NS |
| Body height (cm) | 167 (156–173) | 164 (155–173) | 169 (163–176) | NS | NS |
| TBW (L) | 33 (28–38) | 30 (26–38) | 37 (31–41) | NS | NS |
| SMM (kg) | 24 (21–29) | 22 (19–29) | 24 (18–30) | NS | NS |
| Protein (kg) | 8.6 (7.6–10.2) | 8.1 (6.9–10.2) | 9.1 (7.9–10.5) | NS | NS |
| Minerals (kg) | 3.3 (2.7–3.6) | 2.9 (2.5–3.5) | 3.2 (2.8–3.9) | NS | NS |
| PBF (%) | 26 (21–33) | 16 (12–23) | 14 (12–16) | <0.001 | <0.001 |
| VFA (cm2) | 77 (54–100) | 42 (28–48) | 35 (26–44) | <0.001 | <0.001 |
Values are expressed as median and interquartile range (Me (Q1–Q3). Statistically significant differences between the medians were detected by the Mann–Whitney U test. Abbreviations: metabolic syndrome (MetS), percentage body fat (PBF), skeletal muscle mass (SMM), total body water (TBW), visceral fat area (VFA).
Consumption of selected nutrients with the diet.
| Nutrient | MetS+ ( | MetS− ( | Control Group ( | |
|---|---|---|---|---|
| Me ± IQR | ||||
| Main nutrients | ||||
| Energy (kcal) | 1760 (1697–1924) | 1803 (1574–1916) | 1859 (1735–1935) | N/S |
| Protein (%TDEE) | 20.0 (16.4–20.8) | 18.1 (15.8–20.6) | 16.4 (13.1–18.6) | <0.01 |
| Carbohydrate (%TDEE) | 56.5 (50.8–59.9) | 54.8 (50.6–59.5) | 55.4 (51.5–61.1) | N/S |
| Fat (%TDEE) | 22.8 (20.0–28.1) | 24.3 (21.2–29.1) | 28.1 (23.7–32.4) | <0.01 |
| Fatty acids | ||||
| SFA (g) | 17.6 (14.3–20.7) | 16.4 (15.3–17.5) | 16.0 (15.1–17.9) | N/S |
| Palmitic acid (g) | 10.4 (9.4–11.4) | 10.1 (8.9–11.6) | 9.8(8.6–10.8) | N/S |
| MUFA (g) | 14.2 (11.9–17.7) | 14.2 (11.2–19.2) | 24.6 (20.5–28.5) | <0.001 |
| Oleic acid (g) | 12.3 (10.6–14.8) | 13.1 (10.8–16.3) | 21.4 (16.6–25.4) | <0.001 |
| PUFA (g) | 5.8 (5.0–7.1) | 6.2 (4.6–8.1) | 9.8 (7.4–11.6) | <0.001 |
| LC-PUFA (g) | 0.069 (0.036–0.205) | 0.069 (0.04–0.093) | 0.093 (0.06–0.231) | <0.05 |
| ω-3 (g) | 0.831 (0.569–1.178) | 0.688 (0.554–1.28) | 1.3 (0.948–1.6) | <0.001 |
| ALA (g) | 0.688 (0.524–0.817) | 0.554 (0.478–0.879) | 1.2 (0.822–1.4) | <0.001 |
| EPA (g) | 0.014 (0.006–0.045) | 0.012 (0.007–0.017) | 0.024 (0.008–0.052) | N/S |
| DHA (g) | 0.039 (0.024–0.148) | 0.038 (0.022–0.066) | 0.066 (0.038–0.137) | <0.001 |
| ω-6 (g) | 4.9 (4.2–5.9) | 5.5 (3.9–6.5) | 7.6 (6.1–9.6) | <0.001 |
| LA (g) | 4.8 (4.1–5.9) | 5.5 (3.8–6.4) | 7.3 (6.0–9.4) | <0.001 |
| AA (g) | 0.048 (0.032–0.151) | 0.048 (0.031–0.096) | 0.111 (0.073–0.181) | <0.05 |
| Carbohydrates | ||||
| Glucose (g) | 8.1 (4.0–9.6) | 4.8 (2.6–6.5) | 6.8 (5.1–8.1) | N/S |
| Fructose (g) | 10.1 (4.6–12.9) | 7.3 (4.2–11.1) | 8.3 (6.5–11.0) | N/S |
| Saccharose (g) | 39.5 (30.2–54.8) | 33.1 (13.7–45.0) | 44.1 (35.1–51.6) | N/S |
| Dietary fiber (g) | 18.1 (16.6–21.4) | 18.0 (13.8–20.8) | 19.6 (16.0–23.0) | N/S |
Values are expressed as median and interquartile range (Me (Q1–Q3). Statistically significant differences between the medians were detected by the Mann–Whitney U test. Abbreviations: arachidonic acid (AA), alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), fatty acids (FA), linoleic acid (LA), long-chain polyunsaturated fatty acids (LC-PUFA), metabolic syndrome (MetS), monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA), saturated fatty acids (SFA), total daily energy expenditure (TDEE).
Implementation of nutritional standards for selected nutrients.
| Nutrient | Recommendation | MetS+ ( | MetS− ( | Control Group ( | |
|---|---|---|---|---|---|
| Main nutrients | |||||
| Protein | <10% | 0 (0%) | 0 (0%) | 3 (5%) | <0.05 |
| 10–20% | 15 (75%) | 33 (83%) | 49 (90%) | ||
| >20% | 5 (25%) | 7 (17%) | 3 (5%) | ||
| Protein PolDiab | <15% | 2 (10%) | 6 (15%) | 21 (38%) | <0.01 |
| 15–20% | 13 (65%) | 27 (68%) | 31 (56%) | ||
| >20% | 5 (25%) | 7 (17%) | 3 (6%) | ||
| Fat | <20% | 5 (25%) | 6 (15%) | 4 (7%) | <0.05 |
| 20–35% | 15 (75%) | 33 (83%) | 47 (86%) | ||
| >35% | 0 (0%) | 1 (2%) | 4 (7%) | ||
| Fat PolDiab | <25% | 14 (70%) | 23 (58%) | 20 (36%) | <0.01 |
| 25–40% | 6 (30%) | 17 (43%) | 35 (64%) | ||
| >40% | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Carbohydrates | <45% | 0 (0%) | 2 (5%) | 2 (3%) | N/S |
| 45–65% | 18 (90%) | 37 (93%) | 52 (95%) | ||
| >65% | 2 (10%) | 1 (2%) | 1 (2%) | ||
| Carbohydrates PolDiab | <45% | 0 (0%) | 2 (5%) | 2 (4%) | N/S |
| 45–60% | 16 (80%) | 31 (78%) | 39 (71%) | ||
| >60% | 4 (20%) | 7 (17%) | 14 (25%) | ||
| Carbohydrates ISPAD | <45% | 0 (0%) | 2 (5%) | 2 (4%) | N/S |
| 45–50% | 5 (25%) | 9 (22%) | 9 (16%) | ||
| >50% | 15 (75%) | 29 (73%) | 44 (80%) | ||
| Fatty acids | |||||
| SFA | <10% | 13 (65%) | 29 (73%) | 49 (89%) | <0.05 |
| ≥10% | 7 (35%) | 11 (27%) | 6 (11%) | ||
| MUFA | <10% | 15 (75%) | 29 (73%) | 15 (27%) | <0.001 |
| 10–20% | 5 (25%) | 11 (27%) | 38 (69%) | ||
| >20% | 0 (0%) | 0 (0%) | 2 (4%) | ||
| LA | <3.5% | 19 (95%) | 31 (78%) | 26 (47%) | <0.001 |
| 3.5–4.5% | 1 (5%) | 7 (18%) | 16 (29%) | ||
| >4.5% | 0 (0%) | 2 (4%) | 13 (24%) | ||
| ALA | ≤0.5% | 17 (85%) | 33 (83%) | 23 (42%) | <0.01 |
| >0.5% | 3 (15%) | 7 (17%) | 32 (58%) | ||
| EPA + DHA | ≤250 mg | 17 (85%) | 37 (93%) | 44 (80%) | N/S |
| >250 mg | 3 (15%) | 7 (3%) | 11 (20%) | ||
| PUFA | <6% | 18 (90%) | 39 (97%) | 45 (82%) | N/S |
| 6–10% | 2 (10%) | 1 (2%) | 9 (16%) | ||
| >10% | 0 (0%) | 0 (0%) | 1 (2%) | ||
| Carbohydrates | |||||
| Saccharose | ≤10% | 12 (60%) | 30 (75%) | 30 (55%) | N/S |
| >10% | 8 (40%) | 10 (25%) | 25 (45%) | ||
| Dietary fiber | >19 g | 13 (65%) | 27 (68%) | 26 (47%) | N/S |
| ≥19 g | 7 (35%) | 13 (32%) | 29 (53%) | ||
| Dietary fiber PolDiab | <25 g | 18 (90%) | 39 (98%) | 46 (83%) | N/S |
| ≥25 g | 2 (10%) | 1 (2%) | 9 (17%) | ||
The standards used refer to the Polish guidelines for the general population [17], unless there are separate recommendations for patients with diabetes mellitus (PolDiab—Polish guidelines for diabetics [18], ISPAD—international guidelines for young diabetics [19]). Values are expressed as number and percentage of respondents (n (%)). Statistically significant relationships between the numbers were detected by the chi-squared test. The data in the “Recommendation” column refer to the percentage of total daily energy expenditure. Abbreviations: alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), linoleic acid (LA), metabolic syndrome (MetS), monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA), saturated fatty acids (SFA).
Frequency of consumption of selected groups of food products.
| Food Products | Never | 1–3 Times a Month | Once a Week | Several Times a Week | Once a Day | Several Times a Day | |
|---|---|---|---|---|---|---|---|
| Wheat bread | MetS+ | 0 (0%) | 1 (5%) | 1 (5%) | 5 (25%) | 5 (25%) | 8 (40%) |
| MetS− | 2 (5%) | 2 (5%) | 3 (8%) | 8 (20%) | 6 (15%) | 19 (47%) | |
| Control | 6 (11%) | 2 (4%) | 4 (7%) | 21 (38%) | 15 (27%) | 7 (13%) | |
| Wholemeal bread | MetS+ | 2 (10%) | 3 (15%) | 6 (30%) | 5 (25%) | 1 (5%) | 3 (15%) |
| MetS− | 3 (8%) | 2 (5%) | 8 (20%) | 11 (27%) | 10 (25%) | 6 (15%) | |
| Control | 6 (11%) | 3 (5%) | 6 (11%) | 25 (45%) | 12 (22%) | 3 (6%) | |
| Groats, pasta, rice | MetS+ | 0 (0%) | 2 (10%) | 10 (50%) | 7 (35%) | 1 (5%) | 0 (0%) |
| MetS− | 0 (0%) | 7 (17%) | 12 (30%) | 20 (50%) | 1 (3%) | 0 (0%) | |
| Control | 0 (0%) | 8 (15%) | 9 (16%) | 35 (63%) | 2 (4%) | 1 (2%) | |
| Potatoes | MetS+ | 0 (0%) | 0 (0%) | 0 (0%) | 9 (45%) | 11 (55%) | 0 (0%) |
| MetS− | 0 (0%) | 2 (5%) | 2 (5%) | 21 (52%) | 15 (38%) | 0 (0%) | |
| Control | 0 (0%) | 11 (20%) | 13 (23%) | 25 (46%) | 4 (7%) | 2 (4%) | |
| Red meat | MetS+ | 1 (5%) | 7 (35%) | 6 (30%) | 6 (30%) | 0 (0%) | 0 (0%) |
| MetS− | 6 (15%) | 6 (15%) | 5 (12%) | 19 (48%) | 2 (5%) | 2 (5%) | |
| Control | 3 (5%) | 5 (9%) | 15 (27%) | 30 (55%) | 2 (4%) | 0 (0%) | |
| White meat | MetS+ | 0 (0%) | 2 (10%) | 6 (30%) | 11 (55%) | 1 (5%) | 0 (0%) |
| MetS− | 1 (2%) | 3 (7%) | 5 (13%) | 27 (68%) | 2 (5%) | 2 (5%) | |
| Control | 0 (0%) | 2 (4%) | 7 (13%) | 43 (78%) | 3 (5%) | 0 (0%) | |
| Fried products | MetS+ | 1 (5%) | 3 (15%) | 6 (30%) | 5 (25%) | 5 (25%) | 0 (0%) |
| MetS− | 1 (3%) | 4 (10%) | 16 (40%) | 18 (44%) | 0 (0%) | 1 (3%) | |
| Control | 1 (2%) | 6 (11%) | 14 (25%) | 30 (55%) | 4 (7%) | 0 (0%) | |
| Fast-food | MetS+ | 2 (10%) | 11 (55%) | 5 (25%) | 2 (10%) | 0 (0%) | 0 (0%) |
| MetS− | 4 (10%) | 25 (63%) | 10 (25%) | 1 (2%) | 0 (0%) | 0 (0%) | |
| Control | 9 (16%) | 37 (67%) | 8 (15%) | 1 (2%) | 0 (0%) | 0 (0%) | |
| Fruit | MetS+ | 0 (0%) | 0 (0%) | 1 (5%) | 6 (30%) | 9 (45%) | 4 (20%) |
| MetS− | 0 (0%) | 3 (8%) | 0 (0%) | 13 (32%) | 11 (28%) | 13 (32%) | |
| Control | 0 (0%) | 0 (0%) | 2 (3%) | 18 (33%) | 17 (31%) | 18 (33%) | |
| Vegetables | MetS+ | 0 (0%) | 0 (0%) | 2 (10%) | 8 (40%) | 5 (25%) | 5 (25%) |
| MetS− | 0 (0%) | 0 (0%) | 2 (5%) | 13 (33%) | 8 (20%) | 17 (42%) | |
| Control | 0 (0%) | 0 (0%) | 3 (6%) | 17 (31%) | 19 (35%) | 16 (28%) | |
| Beverages with sweeteners | MetS+ | 2 (10%) | 3 (15%) | 3 (15%) | 10 (50%) | 2 (10%) | 0 (0%) |
| MetS− | 9 (22%) | 4 (10%) | 12 (30%) | 9 (22%) | 5 (13%) | 1 (3%) | |
| Control | 13 (24%) | 8 (14%) | 11 (20%) | 12 (22%) | 10 (18%) | 1 (2%) | |
| Energy drink | MetS+ | 13 (65%) | 2 (10%) | 4 (20%) | 1 (5%) | 0 (0%) | 0 (0%) |
| MetS− | 30 (75%) | 3 (7%) | 6 (15%) | 1 (3%) | 0 (0%) | 0 (0%) | |
| Control | 47 (85%) | 5 (9%) | 3 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Abbreviation: metabolic syndrome (MetS).
Figure 4Multivariate correspondence analysis coordinate plot. Abbreviations: continuous glucose monitoring (CGM), continuous subcutaneous insulin infusion (CSII), dimension (dim), estimated glucose-disposal resistance (eGDR), flash glucose monitoring (FGM), glucose monitoring (GM), glycated hemoglobin (HbA1c), multiple daily injections (MDI), metabolic syndrome (MetS), total antioxidant status (TAS), visceral fat area (VFA).